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We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 
2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion 
(UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylat-
ed hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for 
these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% 
and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lip-
id parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning 
spot urine glucose to creatinine ratio (r=–0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin 
treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline 
predicts a better glucose-lowering efficacy of ipragliflozin.
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INTRODUCTION
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new 
class of anti-diabetic drugs that lower the plasma glucose levels 
by inhibiting urinary glucose reabsorption from the proximal 
convoluted tubule [1,2]. 
Few studies to date have determined the predictive factors 
for a better glucose-lowering efficacy of SGLT2 inhibitors [3-
5]. In a previous retrospective study of 302 people with type 2 
diabetes mellitus (T2DM) treated with SGLT2 inhibitors alone 
or in combination for 3 months, the greatest glucose-lowering 
effect was observed in cases with a higher baseline estimated 
glomerular filtration rate (eGFR) and glycosylated hemoglobin 
(HbA1c) level. Moreover, the initial response to treatment was 
an independent predictor of glucose-lowering efficacy after 
SGLT2 inhibitor treatment [3]. In addition, a Japanese study in 
people with T2DM has reported an almost 50% decrease in the 
HbA1c-lowering efficacy with luseogliflozin in people with re-
duced renal function compared with normal function [4].
Notably, however, the clinical variables that predict better 
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glucose-lowering efficacy after SGLT2 inhibitor treatment have 
remained largely unknown. Therefore, we aimed in our pres-
ent study to identify the baseline clinical and biochemical vari-
ables that could effectively predict a better glucose-lowering 
response in T2DM after treatment with the SGLT2 inhibitor, 
ipragliflozin. We had a particular focus in this analysis on uri-
nary glucose excretion (UGE). In addition, we sought to deter-
mine the changes in clinical and biochemical variables that are 
most closely associated with the reduction in HbA1c levels. 
METHODS
Study design
The study protocol was approved by the Institutional Review 
Board of each participating center (IRB approval number of 
the central institution: 2016-0100 in Asan Medical Center) and 
complied with the Declaration of Helsinki and the Interna-
tional Conference on Harmonization Harmonized Tripartite 
Guideline for Good Clinical Practice. This was a 12-week 
phase IV, investigator-initiated, open-label, single-arm multi-
center study conducted in four hospitals in the Republic of Ko-
rea. Informed written consent was obtained from all subjects 
prior to study participation. This study was registered at Clini-
calTrials.gov (NCT02791035).
Participants
We screened 119 people who were treated for T2DM between 
June 2016 and March 2017. People aged 20 to 70 years with a 
HbA1c level of 7% to 9.5% at screening despite receiving stable 
doses of anti-hyperglycemic medications for at least the previ-
ous 8 weeks were eligible. 
A sample size of at least 100 patients was required to ensure 
a power of 80% and the significance level of 5% to detect a cor-
relation coefficient of 0.3 between changes in HbA1c and other 
variables, assuming a 15% drop-out rate [5]. 
Eligible people (n=107) received ipragliflozin and were fol-
lowed up for 12 weeks for efficacy and safety assessments. Of 
those enrolled, 92 people (86%) completed the 12-week treat-
ment. 
Interventions
After a 1- to 3-week screening period, people received once-
daily therapy (in the morning with water) with 50 mg ipra-
gliflozin as an add-on to the background therapy during the 
12-week treatment period. During the study period, vital signs 
and the results of physical examinations and laboratory tests 
including hematology, chemistry, plasma glucose, HbA1c, 
mixed meal test (Mediwell Diabetic Meal; Maeil Dairies Co., 
Seoul, Korea), morning spot urine and 8-hour overnight urine 
were collected at baseline and at the end of the study.
Rescue medications were initiated during the treatment pe-
riod if the HbA1c level was ≥9.5%. A drug compliance level of 
below 70% was defined as non-compliance and these people 
were excluded from the per protocol analysis.
End points and assessments
The primary outcome measure of this trial was the correlation 
between the change in the HbA1c and in the UGE as measured 
using morning spot urine or 8-hour overnight urine samples 
after the 12-week treatment with ipragliflozin. Key secondary 
outcome measures after the 12-week treatment with ipra-
gliflozin included: (1) correlation between the changes in 
HbA1c and other parameters (homeostasis model assessment 
of insulin resistance [HOMA-IR], homeostasis model assess-
ment of β-cell function [HOMA-β], and insulinogenic index); 
(2) changes in the fasting plasma glucose, HbA1c, and body 
weights; and (3) percentage of people achieving the target 
HbA1c level of <7.0%.
Statistical analysis
Differences between groups and before and after treatment 
were evaluated using the student t-test or Mann-Whitney U 
test for continuous variables and the chi-square test for cate-
gorical variables. Multiple linear regression analysis was per-
formed to identify variables that were independently associat-
ed with a change in the HbA1c level. Statistical analyses were 
performed using PASW version 18.0 (SPSS, Chicago, IL, USA). 
A P<0.05 was considered significant.
RESULTS
The mean age of these subjects was 56.5 years and the median 
duration of diabetes was 6 years. Almost all of the people re-
ceived metformin prior to study participation (94.6%) and 
78.3% (n=71) of these cases were receiving dual anti-hypergly-
cemic therapy. After a 3-month treatment with ipragliflozin, 
the body weight, waist circumference, blood pressure, and glu-
cose levels were significantly decreased (all P<0.001) and the 
mean HbA1c levels were reduced from 7.6% to 6.9% such that 
62.0% (n=57) of our study population reached a HbA1c target 
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of <7.0%. In terms of pancreatic β-cell function, no changes 
were observed in the HOMA-β and insulinogenic index after 
treatment. However, HOMA-IR, a representative of insulin re-
sistance, was significantly decreased (P<0.001). As expected, 
the UGE level in the spot urine and 8-hour overnight urine 
was increased (Table 1).
We next divided the study participants into two groups in 
accordance with a median HbA1c reduction of 0.7% and 
sought to determine which baseline variables better predicted 
the glucose-lowering efficacy of ipragliflozin treatment. We 
found however that no baseline variables, including the UGE 
level and eGFR, were associated with better hypoglycemic effi-
cacy following a 3-month ipragliflozin treatment, other than a 
higher baseline HbA1c level (Supplementary Table 1).
To determine if any variables were independently associated 
with a greater HbA1c reduction, multiple linear regression 
analysis was performed that included age and sex as well as 
variables found to be possibly related to the HbA1c reduction 
in simple linear regression analysis (Supplementary Table 2). 
The results indicated that a higher baseline HbA1c level and 
lower UGE were independent predictors of a better glucose-
lowering effect of a 3-month ipragliflozin treatment (Table 2). 
Lastly, Spearman correlation analysis was performed to de-
termine the association between HbA1c reduction and chang-
es in clinical and laboratory variables after ipragliflozin treat-
ment, However, no variable including a UGE change was 
found to correlate with a change in the HbA1c level (Supple-
mentary Table 3).
Table 1. Efficacy of a 3-month ipragliflozin treatment
Variable Before treatment After 3-month treatment P value
Body weight, kg 71.5±12.4 70.1±12.2 <0.001
Waist circumference, cm 92.8±11.3 90.3±9.1 <0.001
Systolic blood pressure, mm Hg 126.8±11.4 124.6±11.6 <0.001
Diastolic blood pressure, mm Hg 79.9±10.2 79.3±10.6 <0.001
Total cholesterol, mg/dL 154.8±37.2 148.5±33.1 <0.001
HDL-C, mg/dL 49.0±14.3 50.7±14.2 <0.001
Triglyceride, mg/dL 137.0 (100.0–198.0) 129.5 (90.5–184.8) 0.082
LDL-C, mg/dL 73.3±31.1 67.3±24.7 <0.001
Non-HDL-C, mg/dL 106.8±35.3 98.0±30.9 <0.001
HbA1c, % 7.6±0.5 6.9±0.4 <0.001
Estimated GFR, mL/min/1.73 m2 83.8±17.7 86.8±19.9 <0.001
Meal tolerance test
   HOMA-IR 2.96 (1.80–4.82) 2.03 (1.39–3.52) <0.001
   HOMA-β 33.7 (24.1–46.4) 37.4 (23.7–54.3) 0.190
   Insulinogenic index 0.49 (0.29–0.72) 0.47 (0.26–0.79) 0.642
Urine examination
   8-hr urine glucose/Cr 0.50 (0.11–5.11) 45.19 (28.34–66.38) <0.001
   Morning spot urine glucose/Cr 0.11 (0.07–0.25) 36.08 (24.75–47.92) <0.001
Values are presented as mean±standard deviation or median (interquartile range).
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; GFR, glomerular 
filtration rate; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.
Table 2. Multiple linear regression analysis of HbA1c reduc-
tion
Variable Standardized β P value
Age –0.055 0.524
Female sex –0.083 0.315
HbA1c 0.660 <0.001
HOMA-β% 0.137 0.093
Morning spot urine glucose/Cr –0.299 0.001
HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis model as-
sessment of β-cell function.
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DISCUSSION
In our current single-arm multicenter prospective study of Ko-
rean people with T2DM, we found that a 3-month treatment 
with ipragliflozin decreased 0.7% of the mean HbA1c levels 
and that 62.0% of the people reached the HbA1c target of less 
than 7.0%. In addition, our analysis indicated that ipragliflozin 
treatment reduced not only body weight and blood pressure 
but also lipid parameters. A higher baseline HbA1c value was 
also an independent predictor for a greater reduction in the 
HbA1c level after ipragliflozin treatment. In addition, a lower 
baseline UGE independently predicted a better glucose-lower-
ing efficacy of a 3-month treatment with ipragliflozin.
Previous studies have examined the relationship between the 
renal threshold for glucose reabsorption or UGE with SGLT2 
inhibitor treatment and its glucose-lowering efficacy in people 
with T2DM [6,7]. In an earlier study of 20 Japanese people 
with T2DM, the UGE and blood glucose levels were measured 
before and several hours after a single dose of dapagliflozin, 
which was found to be more effective in younger people. The 
authors speculated that was because younger people have a 
higher UGE than older people and that this could be a marker 
for a better glucose-lowering response to an SGLT2 inhibitor 
[6]. Notably however, another Japanese study of 22 people with 
T2DM came to a different conclusion. In that report, the me-
dian improvement in HbA1c values after a 1-year treatment 
with ipragliflozin was –0.5% and there was a significant inverse 
correlation found between the renal threshold for glucose re-
absorption and the improvement in the HbA1c level (r= 
–0.601, P=0.003) [7]. The authors speculated that as individu-
als with a higher renal threshold for glucose reabsorption have 
a greater capacity to reabsorb urinary glucose from the proxi-
mal tubule, these people may excrete a smaller amount of glu-
cose into the urine [7].
In partial agreement with the aforementioned Japanese 
study [7], ipragliflozin showed a better glucose-lowering effi-
cacy in our present study subjects with a lower baseline UGE. 
In addition, it is well recognized that people with diabetes have 
increased SGLT2 expression and activity [8] and hence that 
glycosuria does not arise in diabetics at the plasma glucose lev-
els that would normally cause the excretion of glucose to urine 
in non-diabetic individuals [9]. Therefore, the lower baseline 
UGE in our better ipragliflozin response group might be due 
to increased SGLT2 expression and/or activity. Similarly, an-
other independent predictor of a higher baseline HbA1c value 
could be associated with increased SGLT2 expression and/or 
activity. Collectively, increased SGLT2 expression and/or activ-
ity caused by hyperglycemia and the consequent decrease in 
the UGE level might be a marker for a better response to 
SGLT2 inhibitors in people with T2DM. Another explanation 
for a lower baseline UGE as a marker for better response to 
SGLT2 inhibitors is that confounding caused by baseline 
HbA1c. In this study, there was a positive correlation between 
baseline HbA1c and UGE (data not shown) and thus, the ad-
justment of baseline HbA1c might remove the confounding 
bias and resulted in unbiased estimate of the coefficient of 
baseline UGE for HbA1c reduction.
This study had several noteworthy limitations. First, this was 
a single arm study without a control group. Second, we only 
evaluated the association between UGE and HbA1c reduction 
after a 3-month ipragliflozin treatment and the association af-
ter longer-term treatments is therefore still uncertain. In addi-
tion, although ipragliflozin increased UGE at all time points 
during a 1-month treatment, the amount of UGE was greatest 
on the following day after the administration of ipragliflozin 
and then gradually decreased [10]. It may therefore be more 
appropriate to determine the association between changes in 
the UGE level and HbA1c reduction at an earlier time point 
after the initiation of SGLT2 inhibitor.
In conclusion, our current findings indicate that the baseline 
HbA1c and UGE are independent predictors of a higher glu-
cose-lowering efficacy of SGLT2 inhibitors and that subjects 
with a lower baseline UGE and higher HbA1c may show the 
greatest benefit from these drugs. 
SUPPLEMENTARY MATERIALS
Supplementary materials related to this article can be found 
online at https://doi.org/10.4093/dmj.2018.0257.
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Supplementary Table 1. Comparison of baseline characteristics according to median HbA1c reduction
Characteristic HbA1c reduction <0.7% (n=44) HbA1c reduction ≥0.7% (n=48) P value
Age, yr 56.1±10.0 56.8±7.8 0.69
Male sex, % 59.1 (26) 60.4 (29) 0.90
Diabetes duration, yr 5.5 (1.3–10.0) 6.0 (2.0–10.0) 0.83
Current smoker, % 20.5 (9) 25.0 (12) 0.60
Alcohol drinking, % 43.2 (19) 43.8 (21) 0.96
Body mass index, kg/m2 26.5±3.9 26.1±3.0 0.59
Body weight, kg 72.2±13.7 70.9±11.1 0.61
Waist circumference, cm 93.4±11.3 92.2±11.4 0.61
Systolic blood pressure, mm Hg 127.2±11.2 126.4±11.8 0.75
Diastolic blood pressure, mm Hg 80.0±10.5 79.8±10.0 0.91
Heart rate, beat/min 77.3±10.8 79.2±9.2 0.37
Aspartate transaminase, U/L 24.3±11.7 27.1±12.6 0.26
Alanine transaminase, U/L 28.6±17.9 31.2±17.4 0.48
Uric acid, mg/dL 5.1±1.4 4.8±1.1 0.27
Total cholesterol, mg/dL 149.9±31.5 159.3±41.6 0.22
HDL-C, mg/dL 49.5±16.8 48.6±11.8 0.75
Triglyceride, mg/dL 127.5 (98.0–200.0) 138.5 (99.5–197.3) 0.62
LDL-C, mg/dL 68.3±20.7 77.5±37.9 0.16
Non-HDL-C, mg/dL 100.4±28.7 111.4±40.2 0.13
HbA1c, % 7.4±0.3 7.7±0.5 <0.01
Estimated GFR, mL/min/1.73 m2 84.5±20.3 83.1±15.0 0.69
Meal tolerance test
   Glucose (0 min), mg/dL 155.6±25.1 145.7±24.7 0.06
   Insulin (0 min), μU/mL 7.5 (4.8–11.8) 8.5 (5.8–12.2) 0.31
   C-peptide (0 min), ng/mL 2.3 (1.6–2.9) 2.2 (1.9–3.0) 0.49
   Glucose (90 min), mg/dL 209.4±38.0 201.6±43.9 0.37
   Insulin (90 min), μU/mL 31.9 (18.6–46.5) 30.7 (19.0–55.1) 0.93
   C-peptide (90 min), ng/mL 5.0 (3.4–6.4) 4.7 (3.7–6.7) 0.85
   HOMA-IR 2.70 (1.60–4.58) 3.02 (1.92–5.48) 0.56
   HOMA-β 31.7 (19.4–42.0) 34.6 (29.4–51.9) 0.08
   Insulinogenic index 0.50 (0.36–0.66) 0.44 (0.26–0.73) 0.53
Urine examination
   8-hr urine Cr, mg/dL 0.57 (0.34–0.80) 0.53 (0.30–0.92) 0.86
   8-hr urine glucose, mg/dL 0.27 (0.04–4.82) 0.43 (0.04–3.06) 0.87
   8-hr urine glucose/Cr 0.34 (0.11–3.00) 1.18 (0.07–5.33) 0.94
   8-hr urine sodium, mmol/L 68.7 (41.4–100.6) 65.5 (41.6–102.5) 0.79
   8-hr urine volume, mL 700 (605–998) 725 (523–1,015) 0.99
   Morning spot urine Cr, mg/dL 129.6 (77.7–186.0) 137.8 (94.8–195.4) 0.27
   Morning spot urine glucose, mg/dL 13.8 (9.1–46.6) 20.8 (11.5–37.6) 0.26
   Morning spot urine glucose/Cr 0.10 (0.07–0.25) 0.13 (0.07–0.29) 0.88
   Morning spot urine sodium, mmol/L 91.5 (62.0–127.0) 95.0 (71.5–119.8) 0.63
Values are presented as mean±standard deviation, percentage (number), or median (interquartile range).
HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; GFR, glomerular filtration 
rate; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.
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Supplementary Table 2. Simple linear regression analysis of 
HbA1c reduction
Variable Standardized β P value
Age 0.05 0.64
Female sex –0.07 0.51
Body mass index 0.07 0.52
Waist circumference 0.05 0.61
Systolic blood pressure –0.04 0.68
Diastolic blood pressure –0.05 0.63
HbA1c 0.60 <0.01
Meal tolerance test glucose 0 min –0.13 0.22
Meal tolerance test glucose 90 min –0.08 0.45
HOMA-IR 0.14 0.20
HOMA-β 0.19 0.07
Insulinogenic index 0.08 0.45
8-hr urine glucose/Cr –0.07 0.51
Morning spot urine glucose/Cr –0.18 0.08
Estimated GFR 0.01 0.96
Glucose filtration rate –0.08 0.46
Glucose excretion rate –0.16 0.14
Renal glucose clearance –0.11 0.29
Fractional glucose excretion –0.08 0.45
HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model as-
sessment of insulin resistance; HOMA-β, homeostasis model assess-
ment of β-cell function; GFR, glomerular filtration rate.
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Supplementary Table 3. Spearman correlation analysis of 
HbA1c reduction with changes in the indicated clinical vari-
ables
Variable r P value
Δ Body weight 0.05 0.65
Δ Waist circumference –0.04 0.68
Δ HOMA-IR –0.08 0.48
Δ HOMA-β% –0.03 0.99
Δ Insulinogenic index 0.11 0.32
Δ 8-hr urine glucose/Cr 0.05 0.62
Δ Morning spot urine glucose/Cr 0.12 0.28
HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model as-
sessment of insulin resistance; HOMA-β, homeostasis model assess-
ment of β-cell function. 
